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Background: Two primary categories of nutritional deficiency exist. An absolute nutritional 
deficiency occurs when nutrient intake is not sufficient to meet the normal needs of the system, 
and a relative nutritional deficiency exists when nutrient intake and systemic levels of nutrients 
are normal, while a change occurs in the system that induces a nutrient intake requirement that 
cannot be supplied from diet alone. The purpose of this paper is to demonstrate that the pri-
mary component of chronic centrally acting monoamine (serotonin, dopamine, norepinephrine, 
and epinephrine) disease is a relative nutritional deficiency induced by postsynaptic neuron 
damage.
Materials and methods: Monoamine transporter optimization results were investigated, re-
evaluated, and correlated with previous publications by the authors under the relative nutritional 
deficiency hypothesis. Most of those previous publications did not discuss the concept of a 
relative nutritional deficiency. It is the purpose of this paper to redefine the etiology expressed 
in these previous writings into the realm of relative nutritional deficiency, as demonstrated by 
monoamine transporter optimization. The novel and broad range of amino acid precursor dosing 
values required to address centrally acting monoamine relative nutritional deficiency properly 
is also discussed.
Results: Four primary etiologies are described for postsynaptic neuron damage leading to a centrally 
acting monoamine relative nutritional deficiency, all of which require monoamine transporter opti-
mization to define the proper amino acid dosing values of serotonin and dopamine precursors.
Conclusion: Humans suffering from chronic centrally acting monoamine-related disease are 
not suffering from a drug deficiency; they are suffering from a relative nutritional deficiency 
involving serotonin and dopamine amino acid precursors. Whenever low or inadequate levels 
of monoamine neurotransmitters exist, a relative nutritional deficiency is present. These pre-
cursors must be administered simultaneously under the guidance of monoamine transporter 
optimization in order to achieve optimal relative nutritional deficiency management. Improper 
administration of these precursors can exacerbate and/or facilitate new onset of centrally acting 
monoamine-related relative nutritional deficiencies.
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Introduction
It is much more desirable to identify, address, and eliminate the cause of a disease than to 
treat its symptoms. Until this research project defined the relative nutritional deficiencies 
associated with disease and dysfunction of the centrally acting monoamines due to low 
or inadequate levels of neurotransmitters, there was no awareness of these nutritional 
deficiencies and no ability to address them properly and optimally.1 The authors of this 
paper have published extensively on the topic of monoamine amino acid precursor 
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management relating to various diseases and dysfunctions. 
Further research in the areas covered in the previous writings 
has revealed a relative nutritional deficiency (RND) etiology 
not previously recognized or reported. The novel concept of a 
monoamine-related RND is developed in this paper.1–13
Serotonin, dopamine, norepinephrine, and epinephrine 
are “centrally acting monoamines” (herein referred to as 
monoamine[s]), and are also involved in the control and 
regulation of peripheral functions.
This novel concept hypothesizes the etiology of chronic 
disease and/or regulatory dysfunctional symptoms to be 
inadequate levels of monoamines as opposed to low levels 
of synaptic monoamines. The RND described herein are 
the most prevalent type of nutritional deficiency afflicting 
humans. An extensive list of diseases, conditions, and dys-
functions has been identified in which synaptic monoamine 
RND are recognized (see Appendix A and Appendix B).1–13 
It is postulated that over 80% of humans suffer from symp-
toms relating to a serotonin and/or catecholamine RND. 
Monoamine-related RND was unrecognized prior to this 
research due to the inability to manage and verify results 
of monoamine transporter manipulation objectively. The 
organic cation transporters (OCT) are the primary determi-
nants of intercellular and extracellular monoamine concentra-
tions throughout the body.
Absolute nutritional deficiency 
versus RND
Two primary categories of nutritional deficiency exist, ie, 
absolute nutritional deficiency and RND.1 Insufficient dietary 
nutrient intake causes absolute nutritional deficiencies. An 
absolute nutritional deficiency can be corrected by optimiz-
ing nutrient intake in the diet. Management of the problem is 
often enhanced by administration of nutritional supplements, 
but they are not required.1
When an RND exists, nutritional intake and systemic 
nutrient levels are normal. However, systemic needs are 
increased above normal by outside forces and cannot be 
achieved by dietary modification alone. Burns and postsurgi-
cal patients are examples where an RND may develop.1
In this paper, the authors discuss the novel finding that 
an RND is the primary etiology whenever there is a chronic 
disease or dysfunction relating to a compromise in the flow of 
electricity through the presynaptic neurons (axons) across the 
synapses then through the postsynaptic neurons (dendrites). 
An extensive list of diseases, conditions, and dysfunctions 
has been identified in which synaptic monoamine RND are 
recognized (see Appendix A and Appendix B).1–13
The monoamine-associated RND is by far the most 
prevalent constellation of nutritional deficiencies found in 
humans (see Appendix A and Appendix B). It is postulated 
that over 80% of humans suffer from symptoms relating to a 
serotonin and/or catecholamine RND. Conditions prior to in 
situ monoamine transporter optimization (MTO, referred to 
in some previous papers as OCT functional status optimiza-
tion) made it impossible to achieve consistent results with the 
administration of monoamine amino acid precursors. With 
the invention and refinement of MTO, the ability to study, 
manipulate, and optimally manage monoamine-related RND 
became clinically possible.1–13
Four primary classes of monoamine-associated RND 
have been identified by this research project:
•	 RND associated with monoamine disease or dysfunction
•	 RND induced by inappropriate administration of amino 
acids
•	 RND induced iatrogenically or by the administration of 
certain drug classes
•	 RND associated with genetic defects or predisposition.
Endogenous versus competitive 
inhibition state
Serotonin and dopamine, and their precursors, exist in 
one of two distinctly unique and physiologically divergent 
states, ie, the endogenous state and the competitive inhibition 
state.1–8,11–13 The monoamine hypothesis advocates that the 
etiology of disease symptoms and/or regulatory dysfunction 
in the endogenous state is low synaptic monoamine con-
centrations which induce trans-synaptic electrical defects. 
Under this model, an absolute nutritional deficiency type 
of approach is advocated, where simply returning synaptic 
monoamine levels to normal corrects the electrical prob-
lem, leading to relief of disease symptoms. None of this 
is true. There is no documentation illustrating that merely 
establishing normal synaptic neurotransmitter levels is 
effective in correcting an electrical defect.1
Subjects in the endogenous state, with and without 
monoamine-related disease, if not suffering from a monoam-
ine-secreting tumor, cannot be differentiated by laboratory 
monoamine assays including MTO. Statistical distribution of 
monoamine levels are the same in subjects with and without 
disease.1,5,7,11
The term “competitive inhibition” refers primarily to inter-
action between monoamines and their amino acid precursors in 
synthesis, metabolism, and transport. The competitive inhibi-
tion state occurs when significant amounts of serotonin and dop-
amine amino acid precursors are   administered simultaneously. 
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The daily dosing values of serotonin and/or dopamine   precursors 
required for the system to enter into the competitive inhibition 
state cannot be achieved by diet alone. When the etiology 
of chronic symptoms is postsynaptic electrical compromise, 
the system needs to be placed into the competitive inhibition 
state in order to elevate synaptic monoamines high enough 
to compensate for the postsynaptic damage.   Optimization of 
synaptic monoamine levels in order to facilitate optimal flow 
of electricity is only possible with simultaneous administration 
of serotonin and dopamine precursors guided by MTO.1–8,11–13
Etiologies of postsynaptic  
neuron damage
Significant damage to the postsynaptic neurons of the sero-
tonin and catecholamine systems may theoretically have 
numerous etiologies. The most common1 are (in order of 
frequency of occurrence):
•	 neurotoxin-induced
•	 trauma-related
•	 biology-related
•	 genetic predisposition.
These four categories interact and are interconnected. For 
example, patients suffering from the genetic disease Charcot-
Marie-Tooth, which afflicts approximately 1 in 2500 humans, 
have a list of over 50 drugs that are potentially neurotoxic in 
the presence of this genetic state but are not toxic to patients 
without the genetic disorder.14
In patients suffering from chronic monoamine-related 
disease, there is permanent damage to the structures of 
the postsynaptic neurons that conduct electricity, such as 
occurs in Parkinson’s disease.1 This damage is permanent 
and does not spontaneously reverse with time. Parkinson’s 
disease is not the only monoamine-related disease where 
humans suffer significant permanent postsynaptic damage.6 
Based on MTO results, virtually all patients with chronic 
monoamine-associated disease have permanent postsynaptic 
damage caused by outside forces.1
Synaptic monoamine levels
These monoamines do not cross the blood–brain barrier. Drugs 
do not increase the total number of monoamine   molecules 
in the brain; their mechanism of action only facilitates 
movement of monoamines from one place to another. The 
only way to increase the total number of monoamine mol-
ecules in the brain is by administration of their amino acid 
precursors which cross the blood–brain barrier where they 
are then synthesized into new monoamine molecules.1
Serotonin is synthesized from 5-hydroxytryptophan 
(5-HTP) which is synthesized from L-tryptophan. Dopamine 
is synthesized from L-dopa which is synthesized from 
L-tyrosine. Epinephrine is synthesized from norepinephrine 
which is synthesized from dopamine (see Figure 1).1,8
Prior to development of MTO, no method existed to man-
age properly and objectively the amino acid and monoamine 
interaction problems found in Figure 2 that are observed in 
the competitive inhibition state. The very act of administer-
ing amino acid precursors may cause amino acid and/or 
monoamine depletion, leading to an RND. The administration 
of improperly balanced amino acids may lead to an RND 
environment with increased side effects, adverse reactions, 
and suboptimal results.1,8
The key to addressing an amino acid precursor imbalance 
during administration is the novel method of simultaneous 
administration of serotonin and dopamine precursors, along 
with sulfur amino acids in a proper balance, as defined by 
MTO.1,8
Review of the chemical properties of the immediate 
monoamine precursors, L-dopa and 5-HTP, shows that they 
hold tremendous and extraordinary potential in the manage-
ment of RND. L-dopa and 5-HTP are freely synthesized to 
dopamine and serotonin, respectively, without biochemical 
feedback inhibition. Each freely crosses the blood–brain 
barrier. It is possible to achieve any required level of sero-
tonin and dopamine to optimize synaptic monoamine levels 
in the brain with these nutrients. MTO reveals that it is not 
the concentration of monoamines that is critical for optimal 
results; it is the balance between serotonin and dopamine in 
the competitive inhibition state, as defined by MTO, that is 
most critical in re-establishing and optimizing the postsyn-
aptic flow of electricity.1,8
Even though 5-HTP has had increasing usage by physi-
cians, the literature, dating back to the 1950s, has never 
L-tyrosine
Serotonin
Dopamine Norepinephrine Epinephrine
Monoamine neurotransmitters Amino acids
L-tryptophan
L-dopa
5-HTP
Figure 1 Synthesis of serotonin and the catecholamines (dopamine, norepinephrine, and epinephrine).
Abbreviations: 5-HTP, 5-hydroxytryptophan; L-dopa, L-3,4-dihydroxyphenylalanine.
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supported truly successful, consistent, and reproducible use 
of 5-HTP in management of nutritional deficiencies. MTO 
clearly explains this problem, ie, the unbalanced approach 
to the use of amino acid precursors.8
The literature on Parkinson’s disease demonstrates that 
the L-dopa dosing value potential is limited due to side 
effects and adverse reactions. In addition, the effective-
ness of L-dopa wanes with time (tachyphylaxis). While 
L-dopa is recognized as the most effective nutritional 
management for Parkinson’s disease, it is   common to use 
other much less effective alternative   Parkinson’s medica-
tions, such as agonists and metabolic enzyme inhibitors, 
initially and for as long as possible in the management of 
Parkinson’s disease, saving L-dopa for last due to all of the 
problems and side effects associated with its unbalanced 
administration. As noted in previous writings, utilizing 
MTO technology will virtually eliminate all side effects and 
problems associated with L-dopa administration which stem 
from improper balance of serotonin, 5-HTP, L-tryptophan, 
L-tyrosine, and sulfur amino acids.
Optimal 5-HTP and L-dopa results require MTO. It is only 
under these conditions that efficacy increases significantly, 
and side effects virtually resolve or are made manageable.6 
Specific examples of the dominant monoamine depleting 
the nondominant monoamine are listed here and illustrated 
in Figure 2.1,8
•	 5-HTP may deplete dopamine
•	 L-tryptophan may deplete dopamine
•	 L-dopa may deplete serotonin
•	 L-dopa may deplete L-tryptophan
•	 L-dopa may deplete L-tyrosine
•	 L-dopa may deplete sulfur amino acids
•	 L-tyrosine may deplete serotonin
•	 L-tyrosine may deplete 5-HTP
•	 L-tyrosine may deplete sulfur amino acids
•	 Sulfur amino acids may deplete dopamine
•	 Sulfur amino acids may deplete serotonin
MTO in the competitive inhibition state reveals that 
  effecting change to one component will effect change to all 
components of the serotonin-catecholamine system, as depicted 
in Figure 2, in a predictable manner. Unbalanced administration 
of precursors causes the dominant monoamine to exclude the 
nondominant monoamine in synthesis and transport, leading to 
depletion and evolution of an RND relating to the nondominant 
system in the process. A novel finding of this research is that 
when depletion of the nondominant system is great enough, 
the effects of the dominant system will no longer be observed 
at any dosing value. This is a severe RND state.8
The L-aromatic amino acid decarboxylase enzyme 
catalyzes conversion of 5-HTP and L-dopa to serotonin and 
dopamine, respectively. Reviewing Figure 3, administration 
of unbalanced enzyme-dominant dosing values of 5-HTP 
or L-tryptophan will cause the serotonin side of the equa-
tion to dominate L-aromatic amino acid decarboxylase and 
deplete the dopamine/catecholamine side of the equation 
through compromise of synthesis. This causes an RND of 
the nondominant dopamine/catecholamine systems. The 
same is true in reverse with the administration of L-dopa. 
When the dopamine side is dominant at the enzyme relative 
to the serotonin side, a serotonin-related RND will occur (see 
Figures 2 and 3).1–8,11–13
The activity of the monoamine oxidase enzyme system, 
which catalyzes monoamine metabolism, is not static. If 
levels of one system become dominant, monoamine oxidase 
activity will increase, leading to depletion and an associated 
RND of the nondominant system via accelerated metabolism 
(see Figures 2 and 4).1–8,11–13
Serotonin
L-dopa
Dopamine
Aromatic
amino acid
decarboxylase
Tyrosine Tryptophan
5-HTP
Figure  3  Improperly  balanced  amino  acid  precursor  administration  leads  to 
depletion of the nondominant system causing a relative nutritional deficiency of that 
system through competitive inhibition at the L-aromatic amino acid decarboxylase 
by the dominant system during synthesis of serotonin and dopamine. 
Abbreviations: 5-HTP, 5-hydroxytryptophan; L-dopa, L-3,4-dihydroxyphenylalanine.
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Figure 2 Amino acid precursor-induced monoamine relative nutritional deficiency. 
Administration of improperly balanced monoamine precursors and/or sulfur amino 
acids may lead to far reaching relative nutritional deficiencies. This depletion of 
amino acids and monoamines can only be corrected with proper administration of 
nutrients as guided by monoamine transporter optimization. 
Abbreviations: 5-HTP, 5-hydroxytryptophan; L-dopa, L-3,4-dihydroxyphenylalanine.
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Synthesis (Figure 3) and metabolism (Figure 4) of 
  monoamines is dependent on OCT which regulates movement 
of amino acids and monoamines in and out of cellular structures 
where these functions take place. This functional status can only 
be determined in situ with monoamine oxidase.1–8,11–13
OCT-dependent metabolism takes place both inside and 
outside of cells. If one system dominates the transporter, the 
nondominant system will be excluded from transport, leading 
to suboptimal regulation of function secondary to increased 
metabolism, and decreased synthesis of the nondominant system 
(see Figure 5). When unbalanced amino acid precursors and/or 
monoamines are present at the transporter entrance, systemic 
monoamine concentrations, which are dependent on transport, 
will not be optimal. This leads to an amino acid-induced RND 
along with suboptimal regulation of function.1–8,11–13
When the established effects of the dominant system 
  dissipate, secondary to depletion of the nondominant   system, it 
is caused by an amino acid-induced RND associated with the 
nondominant monoamine system. This research has tracked the 
etiology of L-dopa tachyphylaxis to a novel serotonin-related 
RND, ie, serotonin is depleted due to serotonin precursor nutri-
ent needs being greater than can be achieved with an optimal 
diet in the face of L-dopa depletion of serotonin and serotonin 
precursors. This is supported by the novel findings that admin-
istering proper levels of serotonin precursors as guided by 
MTO can reverse L-dopa tachyphylaxis quickly.1–8
Centrally acting monoamine RND
The bundle damage theory notes that damage to the post-
synaptic structural components involved with electrical 
conduction is the primary cause of electrical dysfunction 
associated with the monoamine-related diseases, not low 
synaptic neurotransmitter levels. As previously noted, when 
these electrical dysfunctions are present on a chronic basis, 
monoamine levels and nutrient levels are in the normal 
range on laboratory studies.1,8 The damage to the postsyn-
aptic neurons leads to a compromise in the regulatory flow 
of electricity. When the flow of electricity is compromised 
enough, symptoms and dysfunction develop.1
Parkinson’s disease is a prototype in the study of monoam-
ine-related RND. It is well known that in Parkinson’s disease 
there is damage to the dopamine neurons of the substantia 
nigra in the brain. L-dopa is administered in order to increase 
dopamine levels to compensate for the compromised electri-
cal flow that results from the damage.
MTO evaluation shows that the only viable explanation 
for chronic electrical dysfunctional diseases that are present 
in patients who have normal synaptic monoamine levels is 
damage to the postsynaptic neuron structures (bundle dam-
age theory). This is the classical presentation observed with 
the Parkinson’s disease model where electrical dysfunction 
secondary to postsynaptic neuron damage has been identi-
fied and has caused an RND problem related to inadequate 
intake of the dopamine precursor. It is the novel findings 
of this research project that, as with Parkinson’s disease, 
postsynaptic neuronal damage with the associated RND is 
common in all chronic monoamine-related illnesses for which 
the etiology is electrical dysfunction.6
Prior to management of monoamine RND, the amount 
of nutrients entering the brain is normal but it is not high 
enough to facilitate synthesis of monoamines at the levels 
needed to allow the OCT to function up to the required flow 
potentials encoded in the transporter.
HVA
Dopamine
norepinephrine
epinephrine
Serotonin
5-HIAA
MAO
COMT
Figure 4 Domination of the monoamine oxidase enzyme system by one system 
leads to increased enzyme activity resulting in depletion of the nondominant system 
with an associated relative nutritional deficiency through increased metabolism. 
Abbreviations: COMT, catechol-O-methyltransferase; MAO, monoamine oxidase; 
5-HIAA, 5-hydroxyindoleacetic acid; HVA, homovanillic acid.
To the 
urine
Gate open
To the 
urine
Gate partially closed
Basolateral
monoamine
transporter
lumen
OCT gate-lumen
regulation
Dopamine
phase 2 or 3 at
the transporter.
Competitive
inhibition in
place
Serotonin
phase I at the
transporter. Gate
regulation in 
place
Figure 5 In the competitive inhibition state, organic cation transport of serotonin 
and catecholamines needs to be in proper balance to ensure optimal regulation of 
function and optimal synthesis of both systems and prevent monoamine-induced 
and/or amino acid-induced relative nutritional deficiencies. 
Abbreviation: OCT, organic cation transporters.
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Materials and methods
The primary forces responsible for establishing monoamine 
levels throughout the body are synthesis, metabolism, and 
transport. Transport dominates with its control and regulation 
over synthesis and metabolism.1,8 The first step in the RND man-
agement protocol is simultaneous administration of serotonin 
and dopamine amino acid precursors in dosing values great 
enough to place the monoamine system into the competitive 
inhibition state. Then, 1 week later, a urine sample is obtained, 
monoamine assays are performed, and MTO interpretation is 
done. This enables a proper decision on the modification of 
amino acid dosing values in order to achieve both the serotonin 
and dopamine in the optimal phase 3 ranges.3,4,6,12
If the MTO-guided amino acid dosing value changes do 
not yield the desired results in 1 week, another specimen is 
obtained and submitted for additional MTO-guided dosing 
change recommendations. The optimal phase 3 ranges of 
serotonin and dopamine are achieved with the benefit of 
MTO. This is a complex task because, in the competitive 
inhibition state, changing one amino acid precursor changes 
all components of the equation shown in Figure 2.3,4,6,12
Two or more urinary serotonin and dopamine assays, 
performed on different days while taking different amino acid 
dosing values, are required for absolute MTO verification of 
phases and dosing recommendations. The patient must be 
taking monoamine precursors in significantly varied doses 
for five or more days continuously to allow for equilibration 
of the system to the dosing change. The results of these serial 
assays are then compared to determine the change in urinary 
serotonin and dopamine levels in response to the change in 
amino acid precursor dosing values.3,4,6,12
At the initial visit it is recommended that the follow-
ing adult amino acid dosing values be initiated: L-cysteine 
4500 mg, L-tyrosine 3000 mg, vitamin C 1000 mg, L-lysine 
500 mg, 5-HTP 300 mg, calcium citrate 220 mg, vitamin B6 
75 mg, folate 400 µg, and selenium 400 µg. The pediatric 
dosing values (,17 years) are half the adult dosing values. 
A full discussion of the scientific basis for each of these amino 
acid and cofactor nutrients is covered in previous writings 
by the authors. A brief overview is as follows:
L-tyrosine and 5-HTP are dopamine and serotonin pre-
cursors, respectively. Vitamin C, vitamin B6, and calcium 
citrate are cofactors required in the synthesis of serotonin 
and/or dopamine. Folate is required for optimal synthesis 
of sulfur amino acids. Selenium is given in response to the 
ability of cysteine to concentrate methylmercury in the cen-
tral nervous system. L-lysine prevents loose hair follicles 
in a bariatric medical practice. L-cysteine is administered 
to compensate for L-tyrosine-induced depletion of sulfur 
amino acids.3,4,6,12
The literature verifies that baseline monoamine testing 
in the endogenous state, prior to starting monoamine amino 
acid precursors of serotonin and dopamine, is of no value 
due to lack of reproducibility when monoamine testing is 
performed on multiple days from the same subject. Therefore, 
baseline testing has no place in monoamine-related RND 
management.3,4,6,12
In the competitive inhibition state, laboratory testing 
has reproducibility on successive test dates. MTO can 
assist in selecting the appropriate dose of the respective 
amino acid precursors to achieve the required transporter 
flow of monoamines and amino acids for optimal RND 
management.3,4,6,12
Three-phase transporter response
When postsynaptic damage compromises electrical flow at 
that postsynaptic location, the OCT is encoded with opti-
mal monoamine transporter configuration and flow rates to 
compensate for the damage. When the monoamine flows are 
optimized immediately above the phase 2/phase 3 inflection 
point, as discussed in this section, there is optimal restoration 
of postsynaptic electrical flow. However, when a significant 
RND exists, encoded OCT needs cannot be met by dietary 
intake alone, and this is the basis of the RND.1–13
In the competitive inhibition state, three phases of OCT 
subtype 2 (OCT2) transporter response are observed. The 
status of monoamines in the endogenous state may be referred 
to as phase 0. In phase 0, the serotonin or dopamine entrance 
gates are at maximum closure, although still partially open, 
and the concentrations of monoamine presenting at the 
transporter are too low for the entrance gate to impact access 
of the monoamine to the transporter. In phase 0, the mono-
amines simply access the OCT2 without restriction. Since 
urinary monoamine levels are a measurement of monoamines 
not transported by the OCT2, urinary monoamine levels 
are random in phase 0, not affected by the entrance gate or 
transporter.1–13
Proper use of MTO deciphers the optimal flow of sero-
tonin and dopamine as established by amino acid precursor 
administration which is encoded in OCT2 by the damaged 
system. Proper implementation of MTO revolves around 
identification of the phase 1, phase 2, and phase 3 of both 
urinary serotonin and dopamine responses during administra-
tion of varied amino acid precursor dosing values (the com-
petitive inhibition state). While an experienced interpreter 
may often be able to determine the serotonin and dopamine 
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phases with one test, a high degree of certainty exists 
only when two urinary monoamine assays are compared 
while taking varied amino acid dosing values. Referring to 
Figure 6, in phase 2, the urinary serotonin and dopamine 
levels are low (serotonin ,80 µg and dopamine ,475 µg 
of monoamine per g of creatinine). In phase 1, there is an 
inverse relationship between amino acid dosing and urinary 
monoamine levels. In phase 3, there is a direct correlation 
between amino acid dosing values and urinary monoamine 
levels on assay. The amino acid dosing values where the 
phase inflection points occur is highly variable and unique 
to each individual.1–13
Assayed urinary serotonin and dopamine values are 
reported in µg of monoamine per g of creatinine in order 
to compensate for fluctuations in urinary specific gravity. 
The phase 3 optimal range for urinary serotonin is defined 
as 80–240 µg of serotonin per g of creatinine. The phase 3 
optimal range for urinary dopamine is defined as 475–1100 
µg of dopamine per g of creatinine.1–13 Urine samples are usu-
ally collected 6 hours prior to bedtime, with 4 pm being the 
most frequent collection time point. For most patients, 6 hours 
before bedtime is the diurnal low point of the day.1–13
Organic cation transporters
The authors have published numerous peer-reviewed articles 
on the topic of in situ MTO.1–13 These publications outlined the 
novel first and only in situ methodology for OCT functional 
status determination of encoded transporter optimization in 
humans. This paper establishes the novel RND etiology and 
traits associated with chronic monoamine-associated diseases 
and regulatory dysfunctions, ie, postsynaptic damage-induced 
electrical compromise and the resultant relative RND.
The monoamines and their amino acid precursors are 
moved across cell walls by complex molecules known as 
transporters. Depending on their orientation with the cell 
wall, transporters may move these substances in or out of 
the cells.1
The three primary actions that determine monoamine 
neurotransmitter levels everywhere in the body are synthe-
sis, metabolism, and transport. Transporters dominate and 
regulate synthesis and metabolism. Synthesis is dependent on 
transport of amino acids into the cells. Metabolism depends 
on transporters to move neurotransmitters into the environ-
ment where enzymes break them down. Ultimately, intercel-
lular and extracellular (including synaptic) monoamine and 
amino acid precursor levels are functions of and dependent 
on transporters.1–8,11–13
The following key points establish synaptic monoamine 
neurotransmitter levels. Monoamine neurotransmitters are stored 
in storage vesicles found in the presynaptic neuron. When an 
electrical pulse travels down the presynaptic neuron, it causes the 
vesicles to fuse to the presynaptic neuron cell wall, at which point 
neurotransmitters are excreted into the synapse. This is not the 
controlling event that regulates synaptic neurotransmitter levels. 
The synaptic monoamine levels are a function of simultaneous 
interaction of two transporter types. High affinity transporters are 
found on all neurons where monoamines are synthesized. The 
OCT2 regulates synaptic neurotransmitter levels by transporting 
neurotransmitters that escape high affinity transport. It is the 
OCT2 that essentially fine tunes the intercellular and extracel-
lular monoamine levels of the brain and kidneys. OCT2 are also 
located on the cell membrane of the presynaptic neuron. The 
OCT2 perform the reuptake function, whereby the neurotrans-
mitters are returned back into the presynaptic neurons where 
they are stored in the vesicles, waiting to be released anew on 
impulse into the synapse.15
For many years, laboratories have attempted to decode 
results found when neurotransmitters are assayed. The 
primary approach has been to determine simply whether 
levels were high or low. This did not work because it did not 
take into account the effects of transporters. This high/low 
approach to assay interpretation, as a guide to amino acid 
dosing values, was no more effective than simply giving 
amino acid precursors randomly.5,7,11
There are three specific items1–13 that allow for the validity 
of MTO:
•	 The various subtypes of transporters are “identical and 
homologous” throughout the body.
•	 OCT encoding occurs in an identical and homologous 
manner that facilitates raising levels of monoamines to 
establish levels high enough to relieve symptoms.
•	 Most importantly, OCT2 are found in only a few 
places in the body, mainly the kidneys and synapses of 
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Figure 6 The core part of monoamine transporter optimization, ie, the three 
phases of transporter response to varied amino acid precursor dosing values.
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the brain; they are encoded identically and enable MTO 
  determination to be an effective tool for establishing the 
optimal levels of amino acid precursor administration.
Based on in situ OCT observations, when the patient is 
suffering from chronic monoamine neurotransmitter-related 
disease, MTO is the only method available that allows for 
establishment of balanced serotonin and dopamine neu-
rotransmitter levels needed to compensate optimally for the 
defective electrical flow in the brain and to relieve the RND 
induced by postsynaptic damage.1–13
Most patients, by history, are simultaneously suffering from 
three or more monoamine deficiency diseases.9 This etiology 
is consistent with multifocal RND. The entire clinical picture 
presents as multiple monoamine-related disease, but needs to 
be managed as a single problem with one etiology, ie, a mono-
amine RND relating to suboptimal function of OCT2.1,8
The MTO defines:
•	 The phase of serotonin and dopamine in OCT transport 
in the competitive inhibition state;
•	 the status of the serotonin and dopamine OCT entrance 
gates;
•	 the status of serotonin and dopamine OCT lumen 
saturation; and
•	 the OCT balance status between the monoamines and 
their amino acid precursors.1–13
All four of these functions are critical to determining the 
following in the competitive inhibition state:
•	 Optimal dosing values of serotonin and dopamine amino 
acid precursors.
•	 Facilitation of optimal transport of serotonin and 
catecholamines.
Results
The results shown in the following tables are from urinary 
monoamine assays which demonstrate the extreme individual 
variability of serotonin and dopamine precursor needs in 
monoamine-related RND management under the guidance 
of MTO in order for both serotonin and dopamine to achieve 
the phase 3 optimal ranges.
All three subjects in Tables 1–3 were suffering from 
depression with no other monoamine-related RND states 
present. In all three cases, when both serotonin and dopamine 
were established in the phase 3 optimal ranges, relief of 
depression symptoms was obtained. All three patients noted 
no relief of symptoms until both the serotonin and dopamine 
were established in these ranges.
The US Department of Agriculture recommended daily 
allowances are intended for a normal population to meet 
  minimal daily nutrient needs, ie, to prevent absolute   nutritional 
deficiencies. Proper management of RND is intended to be 
under the care of a physician because achieving a balance of 
neurotransmitters may require administration of nutrients in 
dosing values which are well above the US Department of 
Agriculture recommended daily allowances.16
Serotonin and dopamine amino acid dosing required to 
meet encoded optimal monoamine transporter flow varies 
greatly over large dose ranges. There is no relationship, 
from patient to patient, between the ultimate dosing values 
of serotonin and dopamine precursors required to establish 
serotonin and dopamine concentrations at the optimal flow 
encoded in the OCT.
The following ranges were extracted from a database 
containing over 2.4 million patient-days of amino acid man-
agement experience where monoamine-related RND were 
optimized with MTO. The effective therapeutic range was 
defined as the amino acid dosing values, within two standard 
deviations of the mean, that were associated with serotonin or 
dopamine in the phase 3 optimal range. Excluded from the data 
were patients suffering severe postsynaptic dopamine injury, 
such as Parkinson’s disease and restless leg syndrome.
•	 The daily effective therapeutic range of 5-HTP as evi-
denced by a phase 3 serotonin in the 80 to 240 µg/g 
creatinine range was found to be .0 mg to 2400 mg.
•	 The daily L-dopa effective therapeutic range as evidenced 
by phase 3 dopamine in the 475 to 1100 µg/g creatinine 
range was found to be .0 mg to 2100 mg.
•	 The daily effective therapeutic range of L-tyrosine as 
evidenced by dopamine response to L-dopa administra-
tion was found to be .0 mg to 14,000 mg.
The dosing values of 5-HTP, L-dopa, and L-tyrosine are 
independent of each other. Some variability in the high-end 
range values may occur when individual RND-associated dis-
ease states are examined versus this entire group of diseases. 
Using L-tyrosine as an example, dosing values of 14,000 mg 
per day were unknown in the literature prior to this research. 
However, when amino acid dosing values are established 
with MTO, these seemingly high doses are uniformly well 
tolerated by patients, because electrical flow and the system 
revert back to normal.
Discussion
The OCT2 of the brain fine tunes monoamine neurotransmit-
ter levels. The OCT2 of the brain and kidneys are identical 
and homologous and share certain specific traits, including 
being genetically identical with regard to DNA sequencing.16 
In order to understand the significance of the amino acid 
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dosing value variables found in Tables 1–3, it is necessary to 
review OCT2 transporter physiology.
Serotonin and dopamine transport across the basolateral 
membrane of the proximal convoluted renal tubule cells is 
identical to the mechanism of action in the brain. A high affinity 
transporter is involved and the OCT2 transports and fine tunes 
monoamine neurotransmitter levels not transported by the high 
affinity transporters.17 The urinary assays of Tables 1–3 repre-
sent monoamines that are newly synthesized in the proximal 
convoluted renal tubule cells and are not transported across the 
basolateral membrane by the high affinity OCT2 system. These 
newly synthesized monoamines, not transported by the basolat-
eral transporter system, are transported via the OCTN2 through 
the apical membrane, finally ending up in the urine.1,8
The high affinity OCT2 system in the brain primarily 
functions as the monoamine reuptake transporters located 
on the presynaptic neurons. Synaptic monoamine levels 
represent monoamines that have not been transported into 
the presynaptic neurons. This is a functional transporter 
characteristic of the brain and is identical and homologous 
to OCT2  function of the proximal renal tubule cells. The 
synaptic monoamine levels are analogous to the monoamine 
concentrations found in the urine. Monoamine reuptake 
inhibitor drugs interact with OCT2 transporters.1–13
When postsynaptic damage associated with compromise 
in the flow of electricity occurs leading to development of 
disease symptoms:
•	 An increase in synaptic monoamine levels compensates 
by facilitating the increased flow of electricity.
•	 OCT2 transporters are encoded to establish monoamine 
concentrations required to compensate for the problem. 
This is evidenced by the monoamine/amino acid dosing 
value variability in correlation with the clinical response 
of symptom resolution.
•	 Serotonin and dopamine amino acid precursor adminis-
tration results in synaptic and urinary monoamine levels 
following the three phase response.1–13
As noted in Figure 6, the optimal amino acid dosing val-
ues as identified by MTO places the serotonin and dopamine 
in  phase 3 just above the phase 2/phase 3 inflection point. 
In the optimal phase 3 dosing range, the OCT2 entrance 
gates are fully open, and the flow through the transporter has 
become saturated with serotonin and dopamine. This occurs 
at the phase 2/phase 3 inflection point as the total amount of 
serotonin and dopamine presenting at the transporter entrance 
increases. In the competitive inhibition state, the concentra-
tion of serotonin and dopamine reported on assay is not as 
important as achieving proper balance of the monoamines in 
the optimal phase 3 ranges as defined by MTO.1–13
For example, a serotonin concentration of 230 µg/g 
creatinine may appear to be in the optimal range if only 
concentration values are considered. However, when this 
laboratory value is found to be in phase 1, a completely 
different physiological state emerges, ie, one of suboptimal 
synaptic function and restricted monoamine access to the 
transporter because the system gives priority to elevating 
synaptic monoamine levels at the expense of optimizing 
monoamines stored in the presynaptic vesicles.1–13
Table 1 Patient with depression suffering from postsynaptic serotonin neuronal damage, as evidenced by the level of 5-HTP required 
to control the RND
Urinary serotonin and dopamine reported in μg monoamine per g of creatinine
Amino acids (μg/day)
Date Serotonin Serotonin phase Dopamine Dopamine phase 5-HTP L-dopa L-tyrosine
11/1/2011 873 1 536 3 300 240 3000
1/18/2011 27 2 986 3 600 240 4000
12/4/2011 187 3 491 3 900 120 5000
Abbreviations: 5-HTP, 5-hydroxytryptophan; L-dopa, L-3,4-dihydroxyphenylalanine; RND, relative nutritional deficiency.
Table 2 Patient with depression suffering from postsynaptic catecholamine neuronal damage as evidenced by the level of L-dopa 
required to control the RND
Urinary serotonin and dopamine reported in μg monoamine per g of creatinine
Amino acids (μg/day)
Date Serotonin Serotonin phase Dopamine Dopamine phase 5-HTP L-dopa L-tyrosine
10/4/2011 3392 3 554 1 300 240 3000
10/22/2011 2343 3 283 2 150 480 1500
11/6/2011 216 3 694 3 37.5 720 375
Abbreviations: 5-HTP, 5-hydroxytryptophan; L-dopa, L-3,4-dihydroxyphenylalanine; RND, relative nutritional deficiency.
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Synaptic monoamine levels and presynaptic vesicle mono-
amine levels are a function of OCT2 functional status. When 
compromise in electrical flow is present, the OCT2 is encoded 
with the monoamine transporter flow characteristics required for 
optimal flow through the presynaptic, synaptic, and postsynaptic 
systems. This novel transporter encoding variability is vigor-
ously displayed in Tables 1–3, where MTO defines the required 
optimal serotonin and dopamine amino acid precursors.1–13
A hypothesis of this research states that, in the endog-
enous state, when postsynaptic neuron damage occurs, a 
point is reached where the transporters are unable to alter 
the flow of available monoamines sufficiently to keep the 
electrical flow at a level great enough for the system to 
function normally and the patient to be symptom-free. When 
the total monoamine concentration in the system is normal 
but too low for the transporters to optimize synaptic levels, 
it is the result of an RND of serotonin and/or dopamine; 
this requires resolution with a nutrient-based amino acid 
precursors approach any time low or inadequate levels of 
monoamine neurotransmitters exist.1–13
One of the foundations for monoamine-associated RND 
and the ability to compensate for this problem is illustrated 
in Tables 1–3. The body responds to postsynaptic neuron 
damage by encoding the OCT2 in a unique and individualized 
manner that facilitates synaptic monoamine compensation. 
However, monoamine levels that are high enough to allow 
the OCT2 to compensate are not achievable on a regular diet, 
so the system languishes in the phase 0 state.1–13
By administration of properly balanced nutrients (amino 
acids), optimal synaptic monoamine levels are established 
and relief of symptoms and/or proper regulation of function 
occur. As discussed in the Results section, the amino acid 
dosing values required to achieve optimal OCT2 function 
vary greatly and are very individualized. Once the proper 
amino acid dosing needed to relieve symptoms is found, it 
becomes that patient’s standard nutrient intake requirement 
to compensate for the RND unless further postsynaptic dam-
age is experienced.1–13
The site of postsynaptic neuron damage in the brain 
dictates the nature of the RND and the monoamine-associated 
disease symptoms that are manifest. With   Parkinson’s disease, 
damage occurs in the dopamine neurons of the substantia 
nigra. Patients suffering chronic depression sustain postsyn-
aptic damage to the regions of the brain that control affect 
and mood. This could be a damage-associated RND of the 
serotonin, dopamine, or norepinephrine postsynaptic neurons 
or any combination thereof (Tables 1–3).1–13
The amino acid dosing values found in Table 3 deserve 
some additional reflection. The dosing values of 5-HTP and 
L-tyrosine are novel, and much larger than reported in the 
previous literature. The dosing value of L-dopa for this non-
Parkinson’s patient is relatively large as well. Administration of 
the novel amino acid dosing values needed to properly address 
RND which are this large, with successful resolution of symp-
toms, would not be possible or considered without MTO.
Side effects and adverse reactions due to imbalanced 
administration of amino acid dosing values of this magnitude 
without MTO guidance would prohibit dosing values such 
as this, effectively establishing an amino acid dosing barrier. 
Further, without MTO, there is no objective amino acid dos-
ing value guidance in addressing the RND; it is a random 
event in an environment where individual needs vary on a 
large scale and the dosing needs of serotonin and dopamine 
precursors are independent of each other. When serotonin 
and dopamine levels are increased to levels required to 
address the RND and proper balance is achieved with MTO 
Table 3 Patient with depression suffering from postsynaptic serotonin and catecholamine neuronal damage as evidenced by the levels 
of 5-HTP and L-dopa required to control the RND
Urinary serotonin and dopamine reported in μg monoamine per g of creatinine
Amino acids (μg/day)
Date Serotonin Serotonin phase Dopamine Dopamine phase 5-HTP L-dopa L-tyrosine
8/4/2011 1496 1 362 2 300 240 3000
8/22/2011 1288 1 178 2 600 360 4000
9/6/2011 1213 1 86 2 900 480 5000
10/4/2011 761 1 152 2 1200 720 6000
10/22/2011 364 1 187 2 1500 960 7000
11/6/2011 168 1 248 2 1800 1200 8000
11/23/2011 64 2 417 2 2100 1440 9000
12/9/2011 161 3 513 3 2400 1440 10,000
Abbreviations: 5-HTP, 5-hydroxytryptophan; L-dopa, L-3,4-dihydroxyphenylalanine; RND, relative nutritional deficiency.
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guidance, these amino acid dosing values, such as found in 
Table 3, are exceptionally well tolerated and generate the 
desired result of safely alleviating symptoms. The key is 
proper balance. MTO reveals that if side effects and adverse 
reactions occur during amino acid administration, they are 
not due to a specific amino acid; rather, imbalance between 
the serotonin and dopamine systems is the cause. The lack 
of unmanageable side effects, such as those observed when 
only L-dopa is administered for management of Parkinson’s 
disease, is attributable to the balanced administration of the 
precursors which restore neuronal electrical flow and system 
function to normal.1–13
Administration of proper levels of amino acids does not 
make the patient high or euphoric. In response to establishing 
the serotonin and dopamine in the phase 3 optimal ranges, 
symptoms resolve and the patient simply feels normal. What 
matters is getting the required levels of balanced amino acids 
into the system to compensate for the RND associated with 
the electrical defect under the guidance of MTO without 
regard to how large the amino acid dosing value has become, 
as long as the need is indicated.1–13
Amino acid-induced RND
An RND of the nondominant system occurs when there 
is an improper balance between the serotonin and   dopamine 
amino acid precursors. The three primary forces that 
regulate concentrations of centrally acting monoamines 
  throughout the body are synthesis, metabolism, and 
  transport. The serotonin and catecholamine systems are so 
heavily intertwined in the competitive inhibition state that 
they need to be managed as one system under MTO guid-
ance to achieve optimal results. Changes to one component 
of either system will affect all components of both systems 
in a predictable manner.8
Giving only 5-HTP or only L-dopa or improperly 
balanced serotonin and dopamine amino acid precursors 
(Figure 2) will, over time, create many problems which 
result in needless patient suffering from suboptimal 
monoamine levels, increased side effects, and false expec-
tations during medical care.8
Unbalanced administration of serotonin and dopamine 
amino acid precursors causes:
•	 One system to dominate over the other system in synthe-
sis, transport, and metabolism (see Figures 3–5) leading 
to depletion of the nondominant system.8
•	 Increased incidence of side effects due to administration 
of improperly balanced amino acids.8
•	 The inability to achieve the amino acid dosing values 
needed to optimize MTO fully, which prevents both 
  optimal management of the RND and restoration of 
proper postsynaptic neuron flow.8
Iatrogenic or drug-induced RND
Depletion of monoamine neurotransmitters is known in the 
literature to be associated with administration of reuptake 
inhibitors. Reuptake inhibitors are not just prescription 
drugs used for treatment of depression and attention-  deficit 
disorder, but are also available as street drugs, such as 
amphetamines, “Ecstasy,” and methamphetamine. Reuptake 
inhibitors deplete monoamines via their mechanism of 
action, which induces an RND. All amphetamines also have 
serious neurotoxic potential and are fully capable of induc-
ing a neurotoxin-associated RND, with postsynaptic neuron 
damage in addition to the reuptake inhibitor-driven RND. 
Selective serotonin reuptake inhibitors are also known to 
decrease serotonin synthesis, leading to a drug-induced RND. 
The nonspecific reuptake inhibitor amitriptyline (a tricyclic 
antidepressant) is known to deplete norepinephrine, leading 
to a drug-induced RND.13
A series of illustrations (Figures 7–9) have been posted 
on The National Institute on Drug Abuse’s website. These 
figures show how reuptake inhibitors deplete mono-
amine neurotransmitters leading to the induction of an   
RND.13
Drugs that work with neurotransmitters do not function 
properly if there are not enough synaptic neurotransmitters 
  available. The end stage of reuptake inhibitor-induced 
Figure  7  Prior  to  reuptake  inhibitor  treatment,  inadequate  levels  of 
neurotransmitters  in  the  synapse  cause  a  disease-associated  relative  nutritional 
deficiency leading to compromised electrical flow through the postsynaptic neurons 
resulting in suboptimal regulation of function and/or development of symptoms.
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RND occurs when there is severe depletion of the 
neurotransmitters:
•	 Drug stops working.
•	 Discontinuation syndrome is so strong that the patient 
cannot discontinue the drug even though there is no 
perceived benefit.
•	 Suicidal ideation develops.
When this happens, administration of properly balanced 
serotonin and dopamine amino acid precursors will correct 
the RND, restore the effects of the drug, and restore the 
normal functioning of the system.13
Disease-induced RND
Inadequate flow of postsynaptic electricity is associated 
with virtually all chronic monoamine-related diseases. 
In all cases where synaptic monoamine levels are normal but 
not adequate such as states where low or inadequate levels of 
monoamine neurotransmitters occur, there is a monoamine-
associated RND. Even with the use of reuptake inhibitor drugs, 
proper management of these problems involves addressing the 
RND by administering the monoamines and their amino acid 
precursors. Optimization can only be achieved with MTO.
The ability of MTO to address monoamine-related 
RND is so definitive that proper implementation leads, 
with absolute certainty, to determining whether monoam-
ine neuronal electrical dysfunction is a component of the 
disease picture. The examples below illustrate how proper 
application of monoamine transport optimization can lead 
to recognition and resolution of the RND and also allow 
for observation of other problems not clearly anticipated as 
disease etiologies.
Major affective disorder
Chronic major affective disorder (depression) has an RND 
present which leads to monoamine levels in the central ner-
vous system being too low to achieve optimal postsynaptic 
flow of electricity. Properly balanced amino acid precursors 
are necessary; dietary nutrient intake alone is not sufficient 
to establish high enough monoamine levels to optimize 
transporter-dependent synaptic monoamines.9,12
Contrary to the popular assertion that 5-HTP is indicated 
for depression, MTO reveals that use of only 5-HTP for 
depression is contraindicated. Many patients with depression 
respond only to drugs with dopamine and/or norepinephrine 
reuptake inhibition properties. Administration of only 5-HTP 
leads to an amino acid-induced RND of the catecholamines 
which leads to exacerbation of depression, especially in 
patients whose depression is dominated by catecholamine 
dysfunction. Use of only 5-HTP depletes catecholamines. 
When catecholamine depletion is great enough, any clinical 
benefits initially observed with the administration of 5-HTP 
will be no longer present.1–13
Reuptake inhibitors have only marginal effectiveness in 
addressing the symptoms associated with depression and 
no ability to address the etiology of the RND. In double-
blind studies of major affective disorder, only 7%–13% of 
patients achieve symptom relief greater than placebo. Drug 
administration reveals subgroups of patients suffering from 
major affective disorder who achieve greater efficacy with 
a serotonin, dopamine, or norepinephrine reuptake inhibitor 
or combination. The area of the brain that controls affect 
involves interactions of all three of these monoamines. The 
mechanism and site of action in the affected area of the 
Figure 8 Administration of reuptake inhibitors blocks monoamine transport back 
into the presynaptic neurons. This leads to a net redistribution of neurotransmitter 
molecules from the presynaptic neuron to the synapse. The increased synaptic level 
of monoamines increases post-synaptic flow of electricity leading to restoration of 
adequate regulation of function and/or relief of symptoms.
Figure 9 The drug-induced relative nutritional deficiency. When the monoamines 
are in the vesicles of the presynaptic neuron, they are not exposed to the enzymes 
that catalyze metabolism (monoamine oxidase and catechol-O-methyltransferase). 
They are safe from metabolism. When they are relocated outside the vesicles of 
the presynaptic neuron, they are exposed to these enzymes at a greater frequency. 
Reuptake  inhibitors  create  a  mass  migration  of  monoamines  causing  increased 
metabolic enzyme activity and metabolism of monoamines. This leads to the drug-
induced relative nutritional deficiency if significant amounts of balanced serotonin 
and dopamine precursors are not coadministered with the reuptake inhibitor.
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brain will dictate which of these monoamines are primarily 
involved. While recognizing that any of several monoamines 
may be involved while displaying identical symptomatol-
ogy, the exact determination of which ones are primarily 
involved is not required. The MTO approach simultane-
ously optimizes levels of all three of these monoamines in 
transport, based on interpretation of information encoded in 
the transporters.9,12,13
Standard management for many patients with depression 
includes prescribing reuptake inhibitor antidepressants. If 
proper levels of nutrients are not administered concomitantly 
with the drug, monoamine neurotransmitter depletion may 
and often does occur, leading to a drug-induced RND.9,12
Two primary types of depression are recognized here, 
ie, major affective disorder and bipolar disorder cycling on 
the depressive pole (bipolar depression). As was previously 
noted in the literature, when OCT serotonin and dopamine 
levels were established with MTO in the optimal phase 3 
ranges, all subjects whose depression did not resolve were 
suffering from bipolar depression.12
A review of the clinical history prior to initiation of man-
agement revealed that these patients had no response to bipolar 
medications in the past and had no response when amino acids 
were optimized. These patients had all been treated with a 
mood-stabilizing drug without success. This is an RND that 
requires both serotonin and dopamine to be placed in the 
phase 3 optimal ranges before the effects of mood-stabilizing 
drugs are observed. When the amino acid dosing values 
required for MTO were achieved and a mood-stabilizing drug 
(lithium 300 mg twice a day or valproic acid 250 mg two or 
three times a day) was added, .98% of cases experienced 
resolution of depressive bipolar symptoms in 1–3 days. These 
bipolar depressive patients were suffering from damage at a 
central nervous system site distinctly different from that of 
major affective disorder. Bipolar patients require addition of a 
mood-stabilizing drug that had previously yielded no benefit 
but became effective once the RND was properly addressed 
with the aid of MTO.12
Parkinson’s disease
Standard medical management of Parkinson’s disease uses 
L-dopa and carbidopa. This approach literally turns into a 
case study of how many iatrogenic side effects and adverse 
reactions can be amassed during amino acid mismanage-
ment of patients. Under this approach, traditionally there 
is a total disregard for the interactions of L-dopa and the 
peripheral monoamine status induced by carbidopa (see 
Figure 2).6
L-dopa is recognized as the most effective management 
option for Parkinson’s disease, but is generally not used first-
line due to the exceptionally large amount of iatrogenically 
induced significant side effects and problems that evolve over 
time. Previous literature published by the authors asserts that 
virtually all of the problems associated with administration 
of L-dopa and/or carbidopa are caused by iatrogenic mis-
management of the large number of RND associated with 
the disease, L-dopa, and/or carbidopa. These RND involve 
all three major classes of RND, ie, disease-associated, amino 
acid-induced, and drug-induced.6
The Parkinson’s disease-associated RND is character-
ized by damage to the postsynaptic dopamine neurons of 
the substantia nigra. The extremely high synaptic dopamine 
levels required to restore normal flow of electricity cannot 
be established by dietary intake alone.6
Parkinson’s disease-associated RND management may 
require L-dopa dosing values up to 200 times greater than 
the needs of other monoamine disease processes, as high as 
25,000 mg per day. MTO reveals that the OCT2 are encoded 
to elevate synaptic dopamine vigorously, to the point that 
serotonin is excluded from the transporter leading to devel-
opment of a Parkinson’s disease-associated serotonin RND. 
Other   Parkinson’s disease RND include norepinephrine and 
epinephrine which are dependent on dopamine levels for 
synthesis and are inadequate when the disease is present.6
The three primary monoamine RND associated with 
  Parkinson’s disease are shown in Figure 10. The only practi-
cal way to increase the depleted levels of monoamines and 
amino acids noted in Figure 10 is by administration of amino 
acid precursors guided by MTO.6
Administration of L-dopa is also known to induce RND 
associated with L-tyrosine, sulfur amino acids, L-tryptophan, 
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Figure  10  Basis  for  multiple  relative  nutritional  deficiencies  associated  with 
Parkinson’s disease.
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5-HTP, and serotonin (see Figure 2).6 The following are 
  previously published categories of L-dopa-associated problems 
that are now correlated with an L-dopa-associated RND.6
Serotonin-related RND induced by L-dopa
A serotonin RND is the primary reason the L-dopa quits func-
tioning (tachyphylaxis, ie, L-dopa stops working).6 L-dopa 
tachyphylaxis is precipitated by depletion of serotonin when 
dominant levels of L-dopa are   administered. Administration 
of 5-HTP to restore the balance guided by MTO is required 
to manage this RND properly.
RND-induced transport imbalance between 
serotonin and dopamine
This RND-related problem is responsible for a number of 
side effects associated with the administration of L-dopa in 
a dominant manner, ie, nausea, vomiting, anorexia, weight 
loss, decreased mental acuity, depression, psychotic epi-
sodes including delusions, euphoria, pathological gambling, 
impulse control, confusion, dream abnormalities including 
nightmares, anxiety, disorientation, dementia, nervousness, 
insomnia, sleep disorders, hallucinations and paranoid 
ideation, somnolence, memory impairment, and increased 
libido.6
An imbalance in the administration of serotonin and 
dopamine amino acid precursors is responsible for all of 
the above listed side effects and adverse reactions. MTO is 
required when serotonin precursors are started in combina-
tion with L-dopa. Several of the side effects, such as nausea, 
may be caused by administering the serotonin amino acid 
precursor at levels that are either too high or too low. Since 
the status of serotonin could be too high or too low, the level 
cannot be empirically determined and MTO is required.
L-tyrosine RND
L-tyrosine RND may contribute to the associated on-off 
effect, motor fluctuations, or dopamine fluctuations.6 MTO 
has identified fluctuations in dopamine transport that respond 
to L-tyrosine administration. The etiology of this phenom-
enon remains unknown.
L-dopa-induced sulfur amino acid RND
L-dopa-induced sulfur amino acid RND is associated with 
bradykinesia (epinephrine depletion implicated), akinesia, 
dystonia, chorea, extrapyramidal side effects, fatigue, abnor-
mal involuntary movements, and depletion of glutathione, 
potentiating further the dopamine neuron damage done by 
neurotoxins.6 Patients with Parkinson’s disease as a group have 
significantly depleted sulfur amino acid levels, leading to an 
associated RND which is exacerbated by administration of 
L-dopa. Neurotoxins are the leading etiology of postsynaptic 
dopamine damage in Parkinson’s disease. Glutathione is the 
body’s most powerful toxin-neutralizing agent and is synthe-
sized from sulfur amino acids. When a sulfur amino acid RND 
occurs, it may accelerate the progression of   Parkinson’s disease 
due to increased susceptibility to further neurotoxic insult.
Carbidopa-induced peripheral serotonin  
and catecholamine RND
Carbidopa-induced peripheral serotonin and catecholamine 
depletion cause RND that are associated with numerous 
side effects and adverse reactions, ie, dyskinesia, glossitis, 
leg pain, ataxia, falling, gait abnormalities, blepharospasm 
(which may be taken as an early sign of excess dosage), 
trismus, increased tremor, numbness, muscle twitching, 
peripheral neuropathy, myocardial infarction, flushing, 
oculogyric crises, diplopia, blurred vision, dilated pupils, 
urinary retention, urinary incontinence, dark urine, hoarse-
ness, malaise, hot flashes, sense of stimulation, dyspepsia, 
constipation, palpitation, fatigue, upper respiratory infec-
tion, bruxism, hiccups, common cold, diarrhea, urinary 
tract infections, urinary frequency, flatulence, priapism, 
pharyngeal pain, abdominal pain, bizarre breathing patterns, 
burning sensation of tongue, back pain, shoulder pain, chest 
pain (noncardiac), muscle cramps, paresthesia, increased 
sweating, falling, syncope, orthostatic hypotension, asthenia 
(weakness), dysphagia, Horner’s syndrome, mydriasis, dry 
mouth, sialorrhea, neuroleptic malignant syndrome, phle-
bitis, agranulocytosis, hemolytic and nonhemolytic anemia, 
rash, gastrointestinal bleeding, duodenal ulcer, Henoch-
Schonlein purpura, decreased hemoglobin and hematocrit, 
thrombocytopenia, leukopenia, angioedema, urticaria, 
pruritus, alopecia, dark sweat, abnormalities in alkaline 
phosphatase, abnormalities in serum glutamic oxaloacetic 
transaminase (aspartate aminotransferase), serum glutamic 
pyruvic transaminase (alanine aminotransferase), abnormal 
Coombs’ test, abnormal uric acid, hypokalemia, abnormali-
ties in blood urea nitrogen, increased creatinine, increased 
serum lactate dehydrogenase, and glycosuria.6
The problem in this category is a carbidopa-induced 
RND of peripheral serotonin and catecholamines, and is 
best managed by not using carbidopa in the first place. It is 
not needed when MTO is properly utilized. Carbidopa was 
originally employed in an effort to control the nausea asso-
ciated with L-dopa administration, a side effect and RND 
manageable by MTO.
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Carbidopa inhibits peripheral synthesis of serotonin and 
catecholamines by L-aromatic amino acid decarboxylase. 
In the process, peripheral monoamines develop an associ-
ated RND with a plethora of symptoms (see above). By far, 
the largest group of RND-related side effects and adverse 
reactions in the management of Parkinson’s disease are due 
to carbidopa-induced RND. All of the reasons for which 
carbidopa is added to L-dopa can be safely and easily man-
aged with MTO.6
Attention-deficit hyperactivity  
disorder RND
Double-blind, placebo-controlled studies of attention-deficit 
hyperactivity disorder (ADHD) have revealed drug efficacy 
(reuptake inhibitor and stimulant) greater than placebo in 
14%–41% of patients studied.4
Drug treatment revolves around administration of reuptake 
inhibitors, such as atomoxetine (a norepinephrine reuptake 
inhibitor) and stimulants. The stimulants are divided into two 
classes, ie, amphetamine and nonamphetamine. Both classes 
have dopamine and norepinephrine reuptake properties, along 
with the potential for neurotransmitter depletion.4 ADHD 
patients are exposed to drug-induced RND:
•	 from reuptake inhibitors which deplete neurotransmitters
•	 from the amphetamines (neurotoxins) which cause brain 
damage.
All of this is avoided with the amino acid administration 
approach guided by MTO, because ADHD responds well to 
this RND.4 A previous study indicated that pediatric ADHD 
management with amino acid administration guided by MTO 
which addressed the associated monoamine RND may be 
more effective than methylphenidate and atomoxetine.4
Crohn’s disease RND
Crohn’s disease is a prototype for studying genetically 
associated RND. There is a known genetic defect of OCTN1 
and OCTN2 transporters in the proximal and distal colon of 
patients suffering from Crohn’s disease. As with the OCT, the 
OCTN is capable of transporting organic cations, including 
serotonin, dopamine, and their precursors. In Crohn’s disease, 
the serotonin content of the mucosa and submucosa of the 
proximal and distal colon is significantly increased. The only 
reasonable explanation, as verified by clinical response, is 
that the OCTN1 and OCTN2 genetic deficits induce increased 
synthesis and tissue levels of serotonin. Based on MTO 
with Crohn’s patients, it appears that a severe imbalance 
between high serotonin levels and RND-associated dopamine 
  transport, synthesis, and metabolism contributes significantly 
to disease symptoms. The literature suggests that much of the 
clinical constellation found with Crohn’s disease is induced 
by serotonin toxicity in the colon exacerbated by dopamine-
related RND that exist simultaneously.3 Control of the disease 
symptoms and resolution of all gut lesions has been shown to 
occur with proper MTO-guided balanced amino acid dosing, 
without the use of any drugs and in cases where conventional 
drugs have had no positive effect.3
Other diseases
The rest of the diseases and regulatory functions listed 
in Appendix A and Appendix B share the same basic 
approach to diagnosis, etiology, and RND management. 
If a monoamine-related RND is suspected where synaptic 
monoamine levels are not high enough to compensate for 
postsynaptic electrical defects, the amino acid dosing values 
needed to correct the problem can be identified and achieved 
with MTO.
Conclusion
The authors have published multiple papers relating to MTO. 
In the course of further research and writing efforts, it was 
realized that the most basic etiological factors relating to 
monoamine disease had not been previously discussed, ie, 
the presence of RND. The purpose of this paper is to clarify 
how common an etiology RND is and why it needs to be 
considered.
Neurotoxic, traumatic, biological, and genetic compo-
nents that induce permanent brain damage are real. Without 
an objective guidance tool such as MTO, specific problems 
relating to the association of these RND with this damage 
is not properly recognized or managed with either drugs or 
amino acids. Most physicians do not recognize toxicity as 
a cause of these diseases and few understand the existence 
of the common RND-based etiology. The treatment of 
symptoms with drugs, rather than addressing and resolving 
underlying RND with nutrients, leads to gross failures during 
management, prolonged unneeded disability, exacerbation 
of the disease, and morbidity.
Many things are explained by becoming cognizant of 
the role of chronic postsynaptic damage, as associated with 
RND. In double-blind studies of the treatment of depression, 
reuptake inhibitors are only 7%–13% more effective than 
placebo. The monoamine RND model makes sense out of 
that information. Reuptake inhibitors are only able to increase 
transporter-driven synaptic monoamine levels minimally in 
phase 0 which, in the longer term, may lead to monoamine 
depletion after the response.
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The RND models discussed in this paper have   demonstrated 
how the damage might be related to either dopamine, nor-
epinephrine, or serotonin neurons, or a combination of 
these. MTO defines the proper balance of amino acids in 
order to establish adequate synaptic levels of monoamines 
to compensate for postsynaptic damage and the electrical 
deficit, while relieving the etiological RND. It is the goal of 
this writing to stimulate interest and dialog based on these 
novel observations. The ability to address the cause of a 
problem with nutrients is more desirable than only treating 
the symptoms with a drug.
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Appendix A 
Partial listing of central nervous system 
monoamine dysfunction-related diseases
Parkinson’s disease
Obesity
Bulimia
Anorexia
Depression
Anxiety
Panic attacks
Migraine headaches
Tension headaches
Premenstrual syndrome
Menopausal symptoms
Obsessive compulsive disorder
Obsessionality
Insomnia
Impulsivity
Aggression
Inappropriate aggression
Inappropriate anger
Psychotic illness
Fibromyalgia
Chronic fatigue syndrome
Adrenal fatigue/burnout
Hyperactivity
Attention-deficit hyperactivity disorder
Hormone dysfunction
Adrenal dysfunction
Dementia
Alzheimer’s disease
Traumatic brain injury
Phobias
Chronic pain
Nocturnal myoclonus
Irritable bowel syndrome
Crohn’s disease
Ulcerative colitis
Cognitive deterioration
Organ system dysfunction
Management of chronic stress
Cortisol dysfunction
Appendix B
Partial list of peripheral functions 
regulated by serotonin and/or dopamine
Regulation of phosphate
Loss of serotonin transporters associated with irritable 
bowel syndrome
Hyperammonemia
Hyperammonemia associated with retardation
Regulation alterations in diabetes
Regulation of renal function
Regulation of renal hemodynamics
Blood pressure regulation
Potassium regulation
Sodium regulation
ATP regulation
Regulation of receptors outside the central nervous system 
including but not limited to:
•	 adrenal gland
•	 blood vessels
•	 carotid body
•	 intestines
•	 heart
•	 parathyroid gland
•	 kidney
•	 urinary tract
Regulation of renin secretion
Regulation by autocrine or paracrine fashion
Regulation in essential hypertension
Regulation of angiotensin II
Regulatory functions in shock
Regulatory functions in septic shock
Regulation of oxidative stress
Regulation of glomerular filtration
Regulation of functions that strengthen, examples include 
but are not limited to:
•	 bone marrow
•	 spleen
•	 lymph nodes
Regulation of dopamine in bone marrow cells including 
but not limited to:
•	 splenocytes
•	 lymphocytes from lymph nodes
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Regulation of sympathetic nervous system
Regulation of platelet function
Regulation of function in prostate cancer
Regulation of syncope due to carotid sinus hypersensitivity
Regulation of dialysis hypotension
Regulation of cardiophysiological function
Regulation of adrenochromaffin cells
Regulation in hypoxia-induced pulmonary hypertension
Regulation in Tourette’s syndrome
Regulation of drug absorption and elimination
Regulation in pre-eclampsia
Regulation of fluid modulation and sodium intake via 
actions including but not limited to:
•  central nervous system
•  gastrointestinal tract
Regulation of tubular epithelial transport
Regulation of modulation of the secretion and/or action  
of vasopressin, which in turn causes changes in, but not 
limited to:
•  renin
•  aldosterone
•  norepinephrine
•  epinephrine
•  endothelin B receptors
Regulation of fluid and sodium intake by way of “appetite” 
centers in the brain
Regulation in idiopathic hypertension
Regulation of alterations of gastrointestinal tract transport
Regulation of detoxification of exogenous organic cations
Regulation of prolactin secretion
Regulation affecting memory
Regulation of receptors in the central and peripheral 
system
Regulation of fluid and electrolyte balance including but 
not limited to:
•  blood vessels
•  gastrointestinal tract
•  adrenal glands
•  sympathetic nervous system
•  hypothalamus
•  other brain centers
Regulation of phosphorylation of DARPP-32
Regulation of dependent effects of psychostimulants and 
opioids
Regulation of neuronal differentiation
Regulation of neurotoxicity
Regulation of transcription
Regulatory effects on fibroblasts
Regulation of melatonin synthesis in photoreceptors
Cyclic regulation of intraocular pressure
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